Corn-derived carbohydrate inositol hexaphosphate inhibits Barrett's adenocarcinoma growth by pro-apoptotic mechanisms

Oncology Reports

Volumn 19, Issue 2, 2008, Pages 563-566

  McFadden, David W ^a,b   Riggs, Dale R ^a   Jackson, Barbara J ^a   Cunningham, Cynthia ^a  

^a WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

Apoptosis; Barrett's adenocarcinoma; Cellular proliferation; Inositol hexaphosphate

Indexed keywords

CARBOHYDRATE DERIVATIVE; FLUORESCEIN ISOTHIOCYANATE; LIPOCORTIN 5; PHYTIC ACID;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BARRETT ADENOCARCINOMA; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORN; DRUG SAFETY; ESOPHAGEAL ADENOCARCINOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; NITROBLUE TETRAZOLIUM TEST; PRIORITY JOURNAL;

EID: 38749090096     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.19.2.563     Document Type: Article

References (26)

1. Atherfold PA and Jankowski JA: Molecular biology of Barrett's cancer. Best Pract Res Clin Gastroenterol 20: 813-827, 2006.
2. Mehta S, Johnson IT and Rhodes M: Systematic review: the chemoprevention of oesphageal adenocarcinoma. Aliment Pharmacol Ther 22: 759-768, 2005.
3. Buttar NS and Wang KK: Mechanisms of disease: carcinogenesis in Barrett's esophagus. Nat Clin Pract Gastroenterol Hepatol 1: 106-112, 2004.
4. Fox CH and Eberl M: Phytic acid (IP6), novel broad spectrum anti-neoplastic agent: a systematic review. Comp Ther Med 10: 229-234, 2002.
5. Vucenik I and Shamsuddin AM: Protection against cancer by dietary IP, and inositol. Nutr Cancer 55: 109-125, 2006.
6. Graf E and Eton JW: Antioxidant functions of phytic acid. Free Radical Biol Med 8: 61-69, 1990.
7. Shammsudin AM, Yang G-Y and Vucenik I: Novel anti-cancer functions of IP6: growth inhibition and differentiation of human mammary cancer cell lines in vitro. Anticancer Res 16: 3287-3292, 1996.
8. Shamsuddin AM and Vucenik I: Mammary tumor inhibition by IP6: a review. Anticancer Res 19: 3671-3674, 1999.
9. Jenab M and Thompson LU: Phytic acid in wheat bran affects colon morphology, cell differentiation and apoptosis. Carcinogenesis 21: 1547-1552, 2000.
10. Vucenik I, Zhang ZS and Shammsuddin AM: IP6 treatment of liver cancer II. Intra-tumoral injection of IP6 regresses pre-existing human liver cancer xenotransplanted in nude mice. Anticancer Res 18: 4091-4096, 1998.
11. Shammsuddin AM and Yang GY: Inositol hexaphosphate inhibits growth and induces differentiation of PC-3 human prostate cancer cells. Carcinogenesis 16: 1975-1979, 1995.
12. Singh RP, Agarwal C and Agarwal R: Inositol hexaphosphate inhibits growth, and induces G1 arrest and apoptotic death of prostate carcinoma DU145: modulation of CDKI-CDK-cyclin and pRb-related protein-E2F complexes. Carcinogenesis 24: 555-563, 2003.
13. Agarwal C, Dhanalakshmi S, Singh RP and Agarwal R: Inositol hexaphosphate inhibits growth and induces G1 arrest and apoptotic death of androgen-dependent human prostate carcinoma LNCaP cells. Neoplasia 6: 646-659, 2004.
14. Somasundar P, Riggs DR, Jackson BJ and McFadden DW: Inhibition of melanoma growth by hemocyanin occurs via early apoptotic pathways. Am J Surg 190: 713-716, 2005.
15. Rizvi I, Riggs DR, Jackson BJ, Ng A, Cunningham C and McFadden DW: Inositol hexaphosphate (IP6) inhibits cellular proliferation in melanoma. J Surg Res 133: 3-6, 2006.
16. McFadden D, Riggs D, Jackson B and Davis L: In vitro effects of keyhole limpet hemocyanin in Barrett's adenocarcinoma of the esophagus. Am J Surg 186: 552-555, 2003.
17. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63, 1983.
18. Dixon WJ and Massey FJ: Introduction to Statistical Analysis. 4th edition. McGraw-Hill, New York, 1983.
19. Ludbrook J: Multiple comparison procedures updated. Clin Exp Pharmacol Physiol 25: 1032-1037, 1998.
20. De Meester TR: Barrett's esophagus. Surgery 113: 239-241, 1993.
21. Streitz JM Jr, Ellis FH Jr, Gibb SP, Balogh K and Watkins E Jr: Adenocarcinoma in Barrett's esophagus. A clinicopathologic study of 65 cases. Ann Surg 213: 122-125, 1991.
22. Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer Statistics, 2007. CA Cancer J Clin 57: 43-66, 2007.
23. Devesa SS, Blot WJ and Fraumeni JF Jr: Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 83: 2049-2053, 1998.
24. Soldes OS, Kuick RD, Thompson IA, Hughes SJ, Orringer MB, Lannettoni MD, Hanash SM and Beer DG: Differential expression of Hsp27 in normal oesophagus, Barrett's metaplasia and oesophageal adenocarcinomas. Br J Cancer 79: 595-603, 1999.
25. Deliliers GL, Servida F, Fracchiolla NS, Ricci C, Borsotti C, Colombo G and Soligo D: Effect of inositol hexaphosphate [IP(6)] on human normal and leukaemic haematopoietic cells. Br J Haematol 117: 577-587, 2002.
26. Keswani RN, Noffsinger A, Waxman I and Bissonnette M: Clinical use of p53 in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 15: 1243-1249, 2006.